If you searched “MK-677 before and after,” you were probably hoping to see dramatic transformation photos, week-by-week body updates, or user testimonials. We are not going to show you any of those. Dosage Peptide is a research-use-only dosage reference, and staged “before and after” images are among the least reliable forms of evidence for any compound — lighting, hydration, pump, posing, and photo timing can manufacture a “result” that has nothing to do with the molecule. Instead, here is something more useful and more honest: what actual clinical studies of MK-677 (ibutamoren) measured, on what timeline, and where the data stops. This is a scientific summary, not medical advice, and nothing here describes an approved human therapy.
What the research shows over time
MK-677 (ibutamoren, formerly Merck’s MK-0677) is an orally active growth hormone (GH) secretagogue — a ghrelin-receptor mimetic that prompts the pituitary to release more of your own GH. The human data is genuinely clinical (multiple randomized controlled trials), but it measured hormones and body composition, not the kind of visible “transformation” the search term implies. Here is the documented time-course.
First days to weeks (hormonal changes). In a randomized, placebo-controlled dose-finding trial in healthy older adults, 25 mg/day raised mean 24-hour GH by roughly 97% within two weeks and pushed IGF-1 into the young-adult range by four weeks (Chapman et al., 1996). This hormonal shift is the most consistently reproduced effect and it appears quickly.
Weeks to a few months (body composition begins to shift). In obese men given 25 mg/day for eight weeks, IGF-1 rose about 40% and fat-free (lean) mass increased significantly — but total and visceral fat did not change significantly, and glucose tolerance worsened (Svensson et al., 1998). So even the positive body-composition signal is largely water and lean tissue, not fat loss.
Months to years (the largest, longest trial). The most informative study is a two-year, double-blind RCT in 65 healthy adults aged 60–81 (Nass et al., 2008). Over 12 months, fat-free mass rose by about 1.1 kg with MK-677 versus a 0.5 kg decline on placebo, and body weight increased about 2.7 kg. Crucially, that added lean mass did not translate into measurable gains in strength or physical function. A related agonist study in hemodialysis patients confirmed IGF-1 rose roughly 65% versus placebo (Campbell et al., 2018).
| Study (type) | Duration | What was measured |
|---|---|---|
| Chapman et al., 1996 (RCT, healthy elderly, clinical) | 2–4 weeks | 24-h GH up ~97%; IGF-1 restored to young-adult range; fasting glucose rose |
| Svensson et al., 1998 (RCT, obese men, clinical) | 8 weeks | IGF-1 up ~40%; fat-free mass up; total/visceral fat unchanged; glucose tolerance impaired |
| Nass et al., 2008 (2-yr RCT, older adults, clinical) | 12–24 months | Fat-free mass +1.1 kg vs −0.5 kg placebo; weight +2.7 kg; no strength/function gain |
| Cardaci et al., 2022 (single case report, recreational, anecdotal) | 5 weeks | Lean +3.1% but fat +15.4%; LDL +40%, HDL −36%; ALT +205%; testosterone suppressed |
Clinical vs. preclinical vs. anecdotal. The GH/IGF-1 and lean-mass findings above are clinical (human RCTs). The only published account resembling a bodybuilding “before and after” is a single-subject case report in which MK-677 was stacked with the SARM LGD-4033 (Cardaci et al., 2022) — a sample size of one, with the two drugs confounded, and it showed fat mass rising 15% alongside adverse lipid, liver, and testosterone changes. That is anecdotal, not proof of anything.
Realistic expectations
What the data does support: MK-677 reliably raises GH and IGF-1 and produces a modest increase in lean body mass and body weight, much of it intracellular water. What the data does not support: meaningful fat loss, or any gain in strength, power, or physical function — the largest trial specifically found none (Nass et al., 2008). Individual variation is large, and effects on appetite in particular differ widely between people. This is exactly why online “before and after” galleries are misleading for a research compound: they are unblinded, uncontrolled, self-selected (people rarely post non-results), frequently involve simultaneous training, diet changes, or other compounds, and can be staged in a single afternoon. None of that isolates what MK-677 did.
Safety & legal status
Documented safety signals from the trials are consistent and worth taking seriously: increased appetite, transient mild lower-limb edema and muscle pain, rising fasting glucose with reduced insulin sensitivity, and increased cortisol (Nass et al., 2008; Svensson et al., 1998; Chapman et al., 1996). The stacked case report additionally flagged sharply worsened cholesterol and elevated liver enzymes (Cardaci et al., 2022). On status: MK-677 has been studied in humans for Alzheimer’s disease, hip fracture recovery, and fatty liver, but it is not an approved drug for any indication — Merck’s Phase 2 Alzheimer’s program (512 participants) completed without leading to approval (ClinicalTrials.gov NCT00074529), and it remains investigational. It is sold and referenced here strictly as a research chemical, not a supplement or medicine, and growth-hormone secretagogues are prohibited in competitive sport.
Dosage reference
For research-context handling, reconstitution, and the exact figures used across published trials, see our MK-677 (Ibutamoren) dosage chart. To convert concentrations or plan a reconstitution volume, use our peptide dosage calculator. These references are provided for laboratory and educational purposes only and are not instructions for human use.
FAQ
Are there real, verified “before and after” photos of MK-677?
No credible ones. Published research reported body-composition measurements (lean mass, fat mass, weight), not transformation photos. The internet photos you’ll find are unverified, uncontrolled, and often involve training, diet, or additional compounds, so they cannot be attributed to MK-677.
How long until changes appear in studies?
Hormonal changes (GH, IGF-1) appear within days to two weeks (Chapman et al., 1996). Measurable lean-mass changes emerged over roughly 8 weeks to 12 months in trials (Svensson et al., 1998; Nass et al., 2008) — but again, without gains in strength or function.
Does MK-677 burn fat?
The clinical evidence does not show meaningful fat loss. Trials found lean mass and body weight rising while total and visceral fat stayed essentially unchanged (Svensson et al., 1998; Nass et al., 2008).
References
- Nass R, et al. Ann Intern Med. 2008;149(9):601–11. DOI (PMID 18981485)
- Svensson J, et al. J Clin Endocrinol Metab. 1998;83(2):362–9. DOI (PMID 9467542)
- Chapman IM, et al. J Clin Endocrinol Metab. 1996;81(12):4249–57. DOI (PMID 8954023)
- Cardaci TD, et al. Exp Physiol. 2022;107(12):1467–1476. DOI (PMID 36303408)
- Campbell GA, et al. Nephrol Dial Transplant. 2018;33(3):523–30. DOI (PMID 28340044)
- ClinicalTrials.gov NCT00074529 (MK-0677 Phase 2, Alzheimer’s disease, n=512).
Research-use-only. This article summarizes published research for educational purposes and is not medical advice, and does not describe an approved product or claim any human therapeutic or cosmetic effect.
